Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT02288000
PHASE1

Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases

Sponsor: University Hospital, Lille

View on ClinicalTrials.gov

Summary

The early assessment of new drugs for Alzheimer's disease remains difficult because of the lack of predictive end-point. The use of a battery including different parameters could improve this early development of new drugs. Nevertheless, the interest of such a battery should previously be validated with the yet marketed AD drugs.

Official title: Effect of a 15-day Memantine Treatment on Biomarkers of AD in Healthy Volunteers

Key Details

Gender

MALE

Age Range

18 Years - 30 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2016-09-14

Completion Date

2020-12-31

Last Updated

2026-05-05

Healthy Volunteers

Yes

Interventions

DRUG

Memantine

Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.

DRUG

Placebo

the placebo will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.

Locations (3)

CHRU de Lille/ Centre d'investigation Clinique

Lille, France

CIC Marseille

Marseille, France

CIC Toulouse

Toulouse, France